Biohaven Pharmaceutical Holding Co is a biotechnology business based in the US. Biohaven Pharmaceutical Holding Co shares (BHVN) are listed on the NYSE and all prices are listed in US Dollars.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $18.81 |
|---|---|
| 52-week range | $5.54 - $20.00 |
| 50-day moving average | $15.48 |
| 200-day moving average | $14.08 |
| Wall St. target price | $24.20 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-11.85 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.81 from 2023-01-27
| 1 week (2023-01-20) | 2.01% |
|---|---|
| 1 month (2022-12-29) | 30.90% |
| 3 months (2022-10-28) | 22.70% |
| 6 months (2022-07-29) | -87.12% |
| 1 year (2022-01-28) | -85.26% |
|---|---|
| 2 years (2021-01-29) | -77.93% |
| 3 years (2020-01-29) | 50.9 |
| 5 years (2018-01-25) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $1.47 |
| Market capitalisation | $1.3 billion |
TTM: trailing 12 months
We're not expecting Biohaven Pharmaceutical Holding Co to pay a dividend over the next 12 months.
Biohaven Ltd. , a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial to treat spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in Sept 2022. The company was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
